SRPT - Sarepta Net Sales Margin

Sarepta - graphic logo of issuer SRPT

The application of AI in DNA modeling is accelerating drug development, which is driving volatility for Sarepta Therapeutics, Inc. (SRPT). Actual sales margins help filter out speculation, with the current metric standing at -5.90. Leadership in RNA therapy and large-scale investments in gene editing provide a foundation of stability. Doug Ingram's professional management is successfully navigating regulatory hurdles and effectively commercializing innovative products.

Sarepta Corp (SRPT) Net Profit Margin: for the period 07/04/2022 - 11/20/2026

SRPT (Sarepta Therapeutics, Inc.): analytical breakdowns and indicator data

- market value and analyst target forecast:
Fundamental company valuation:Sarepta Therapeutics - SRPT
Finished products of Sarepta Corp

To protect capital amid volatility, it is essential to track net profitability, which determines the portion of profit from every dollar of revenue after all expenses are deducted. By analyzing the company's sales margins, an investor assesses business efficiency, which for Sarepta Therapeutics, Inc. (SRPT) is highlighted by monopoly pricing power over unique gene therapies, allowing the company to maintain high returns due to a lack of market alternatives.

Competitors of Sarepta Therapeutics, Inc. (SRPT)

TEM: Net Sales Margin|Net Profitability Margin Qiagen QGEN|IONS (Isis Pharmaceuticals) - Net Sales Margin|Repligen Inc. - Net Profit Margin|Net Sales Margin RNA|CRSP - Net Margin|GeneDx - Return on Sales by Net Profit|Net Profit Rate RARE|Beam Tx - Net Sales Margin|Net Margin Twist Bioscience|TXG (10x Genomics) - Return on Sales by Net Profit|Intellia Therapeutics, Inc. (NTLA) - Net Sales Margin|Net Margin Stoke Therapeutics Inc|BLFS: Net Profit Rate|Return on Sales by Net Profit WVE (Wave Life Sciences Corp)|Company Sales Margin Maze Therapeutics Corp|Sionna Therapeutics Inc - Return on Sales by Net Profit|PRME (primemedicine.com) - Net Profit Margin|TSHA - Net Margin|QURE (uniQure) - Net Return on Sales|MeiraGTx Corp (MGTX) - Net Margin|Regenxbio - Net Profit Rate|Net Margin solidbio.com|Net Margin ocugen.com OCGN|Net Sales Margin PACB|Benitec - Net Return on Sales|Net Margin Design Therapeutics DSGN|Net Sales Margin Rocket Pharmaceuticals RCKT|Net Profit Margin 4D Molecular Corp|LXEO: Net Margin|KRRO (Korro Bio, Inc) - Return on Sales by Net Profit|Editas Medicine (EDIT) - Net Sales Margin|Net Margin Silence Therapeutics Inc.|Net Return on Sales PRQR (proqr.com)|Net Margin Codexis Bio (CDXS)|Net Sales Margin sangamo.com (SGMO)|Net Margin nautilus.bio NAUT|Company Sales Margin Metagenomi, Inc (MGX)|Precision BioSciences Inc. - Net Sales Margin|GBIO - Net Sales Margin|BOLD: Net Sales Margin|Net Return on Sales XCUR|Net Margin Imunon|Phio Pharmaceuticals - Net Profit Margin|Net Margin Mustang Bio, Inc. (MBIO)|Company Sales Margin TransCode Therapeutics, Inc.|Net Margin Bionano Genomics BNGO|Net Profit Rate APDN|BLUE - Net Margin|Net Profit Margin IPA|Omega Therapeutics, Inc. (OMGA) - Net Margin|Singular Genomics Corp (OMIC) - Net Sales Margin|RGLS (Regulus Therapeutics, Inc.) - Net Sales Margin|SYRS: Net Profit Rate|Return on Sales by Net Profit TBIO (Telesis Bio Inc.)|Net Sales Margin TRACON Pharmaceuticals Inc. (TCON)|Net Margin Unity Bio UBX